According to the research report titled ‘GLOBAL Non-Alcoholic Steatohepatitis (Nash) Biomarker Market 2021-2028’, available with Market Study Report, global non-alcoholic steatohepatitis (NASH) biomarker market is projected is register a hefty CAGR of 21.28% during the forecast period 2021-2028.
 

Worldwide non-alcoholic steatohepatitis (NASH) biomarker market is driven by increasing incidence rates of metabolic comorbidities and subsequent rise in the patient population. Moreover, growing cognizance regarding non-alcoholic fatty liver disease (NAFLD) will unlock new opportunities for businesses in this domain.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3584756/
 

On the contrary, side effects associated with NASH therapeutics and lack of specialized diagnostic tests for NAFLD are negatively impacting the industry outlook, claims the study.
 

Based on type, global non-alcoholic steatohepatitis (NASH) biomarker market is split into hepatic fibrosis biomarker, serum biomarker, oxidative stress biomarker, apoptosis biomarker, and others. Moving on, the industry verticals segmentation comprises diagnostic lab, pharma & CRO, hospital, and academic research key.
 

From a geographical perspective, North America (United States, Canada), Europe (Germany, Italy, France, United Kingdom, Russia, Spain), Asia Pacific (India, China, Japan, South Korea, Australia & New Zealand), Latin America (Mexico, Brazil), and Middle East & Africa (United Arab Emirates, Saudi Arabia, South Africa, Turkey) are the key geographies covered in the research literature.
 

Expert analysts cite that Asia Pacific non-alcoholic steatohepatitis (NASH) biomarker industry size is touted to expand considerably over the projected timeline. Ongoing development of healthcare infrastructure, increased pervasiveness of NASH, improving economic conditions, and rising healthcare awareness in emerging nations like India and China are supporting the regional market growth.
 

Speaking of the competitive landscape, Zydus Cadila, Viking Therapeutics Inc., Siemens Healthineers AG, Pfizer Inc., Novo Nordisk A/S, Novartis AG, Merck & Co., Madrigal Pharmaceuticals Inc., Gilead Sciences Inc., Genfit SA, Bristol Myers Squibb Co., AstraZeneca plc, and Allergen plc are the top-tier players in global non-alcoholic steatohepatitis (NASH) biomarker market sphere.